Success rate of current human-derived gastric cancer organoids establishment and influencing factors: A systematic review and meta-analysis

Table 5 The gastric cancer organoids construction rate from different subgroups

Subgroup	Successful cases	Number of total	Number of study	Success rate (%)	95%CI	P value	I2
Gender
Female	14	23	4	67.0	31.1-95.7	0.31	36.07
Male	22	47	4	46.7	31.5-62.2
Tissue source
Endoscopic biopsy	16	32	3	53.7	27.1-79.5	0.28	37.35
Surgery and ESD	28	40	4	70.9	49.8-88.7
Differentiate type
Poor	27	43	3	64.6	46.0-81.3	0.106	42.54
Moderate	5	15	2	31.0	6.3-61.3
SRCC	6	16	4	32.7	0.6-76.7
pTNM
I-II	3	8	2	38.3	4.1-79.1	0.108	42.54
III-IV	18	28		65.2	45.7-82.7
Enzyme
Liberase TH, TrypLE	47	67	2	71.5	59.3-82.3	0.04	69.27
EDTA, DL-dithiothreitol	34	68	1	50.0	37.6-62.4
Collagenase	30	46	3	72.1	44.4-93.6
Growth factor
B27	103	152	3	68.7	46.9-83.3	0.94	90.53
Non-B27	55	77	3	69.5	45.2-87.8
N-acetylcysteine	111	162	4	71.9	38.2-96.2	0.95	90.52
Non-N-acetylcysteine	47	67	2	71.5	59.3-82.3
Gastrin	111	162	4	71.9	38.2-96.2	0.95	90.53
Non-gastrin	47	67	2	71.5	59.3-82.3
FGF-2	93	134	3	67.4	21.6-99.2	0.98	90.53
Non-FGF-2	65	95	3	67.9	49.2-84.2
Nutlin-3	47	67	2	71.5	59.3-82.3	0.95	90.53
Non-nutlin-3	111	162	4	71.9	38.2-96.2
Y-27632	21	36	2	58.2	41.6-75.0	0.505	90.53
Non-Y-27632	137	193	4	70.0	39.8-93.3

pTNM: Pathological tumor-node-metastasis; CI: Confidence interval; ESD: Endoscopic submucosal dissection; SRCC: Signet-ring cell cancer; FGF-2: Fibroblast growth factor-2.